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Sclerosing epithelioid ﬁbrosarcoma (SEF) is a rare soft tissue sarcoma mostly occurring in extraosseous sites. SEF represents a
clinically challenging entity especially because no standardized treatment regimens are available. Intraosseous localization is an
additional challenge with respect to the therapeutical approach. We report on a 16-year-old patient with SEF of the right proximal
tibia. The patient underwent standardized neoadjuvant chemotherapy analogous to the EURAMOS-1 protocol for the treatment
of osteosarcoma followed by tumor resection and endoprosthetic reconstruction. Histopathological analysis of the resected tumor
showed > 90% vital tumor cells suggesting no response to chemotherapy. Therefore, therapy was reassigned to the CWS 2002
High-Risk protocol for the treatment of soft tissue sarcoma. To date (22 months after diagnosis), there is no evidence of relapse
or metastasis. Our data suggest that SEF may be resistant to a chemotherapy regimen containing Cisplatin, Doxorubicin, and
Methotrexate, which should be considered in planning treatment for patients with SEF.
1.Introduction
Sclerosing epithelioid ﬁbrosarcoma (SEF) is an uncommon
ﬁbrosarcoma of intermediate-grade malignancy and has
lately been recognized as a distinct clinical entity [1]. SEF is
a malignancy of the older adult with a mean patient age of
47 years (range 14–87 years) [2], but onset in adolescence
has also been reported [1, 3]. Only 10% of patients are
younger than 20 years at time of diagnosis. The distribution
between sexes seems to be equal [4]. SEFs mainly present
as tumors of the lower extremities (39%), followed by the
trunk (21%) and upper extremities (14.5%), but also rare
locations like pituitary gland, intraspinal or base of penis
have been described [1–8]. Typically SEF is complicated
by high frequencies of local tumor relapse and distant
metastases (30%–40%) [2–4, 9–11]. Metastases mostly occur
in lung (70%), bone (41%) and soft tissue [2–4]w i t ha
median interval of 7.7 years from diagnosis to ﬁrst apparent
metastasis [1], but according to a recent meta-analysis up to
27% of patients display distant metastases already at time of
diagnosis [2]. In addition, SEF shares the potential forlymph
node metastasis with other epithelioid malignant soft tissue
tumors such as epithelioid sarcoma [12, 13] and epithelioid
malignant peripheral nerve sheath tumor [14]. Follow-up
data indicate that SEF is an aggressive tumor with mortality
rates ranging between 25% and 57% [1, 4].2 Sarcoma
Together with low-grade ﬁbromyxoid sarcoma (FMS)
and hyalinizing spindle cell tumor with giant rosettes [15],
SEF belongs to the rare family of ﬁbrosing ﬁbrosarcomas
only a few pathologists have encountered [16, 17]. Each
of these tumors has distinct clinical features, but they
share common histological components suggesting a close
relationship [15, 18–21]. Histologically, SEF predominantly
consists of epithelioid cells arranged in strands, nests, and/or
sheets, and set in a ﬁbrotic and extensively hyalinized stroma
[4, 15]. The presence of epithelioid cells often leads to diag-
nostic confusion with metastatic carcinoma and malignant
lymphoma [1]. Further diagnostic diﬃculties arise from the
large paucicellular ﬁbrous zones and focal myxoid areas,
features also seen in low-grade FMS [4]. Ultrastructurally,
cells of SEF resemble ﬁbroblasts due to abundant rough
endoplasmic reticulum [22]. Thus, pathologists worldwide
agree to the complexity of the histological picture, which
often leads to equivocal and delayed diagnosis [2–4, 7, 8, 14,
18, 23–29].
The only consistent immunohistochemical ﬁnding is a
strong and diﬀuse reactivity for vimentin, while almost all
other markers are negative [3, 4]. Peculiar to this tumor is
a subset of cases that stain for EMA [1, 3, 8], a ﬁnding that
may be related to the tumor’s epithelioid phenotype. Some
rare cases express NSE [1, 29] or S-100 protein [1, 20, 27];
however, staining is weak or merely focal. In their study
of 25 cases, Meis-Kindblom et al. concluded that SEF is
a relatively low-grade ﬁbrosarcoma that is fully malignant
despite the presence of histologically benign appearing foci
[1]. In a recent case study metastases of a SEF presented
with a much higher proliferative activity indicated by 60% of
the tumor cells staining positive for the proliferation marker
Ki-67 versus 7%-8% of the primary tumor [28]. In other
cases even lower initial Ki-67-positivity was observed (1%–
6%) [31]. These ﬁndings suggest that SEF can progress to
much more aggressive phenotypes [28]. Moreover, Jiao et al.
could detect strong immunoreactivity with murine double
minute 2 (MDM2) in the absence of p53 mutations in one
case, pointing to a possible role of MDM2 overexpression in
tumorigenesis of SEF [22].
2. The Case
We report on a 16-year-old female who presented with
a four-week history of persistent and progressive load-
dependent pain focused on the right proximal tibia. On
physical examination, no signs of inﬂammation or other
malfunctions could be seen. Conventional X-rays of the
right tibia revealed a 4 × 4cm osteolytic cavity, which
was presumptively diagnosed as a benign lesion. Thus,
open biopsy was carried out, and pathological diﬀerential
diagnosis of an ossifying ﬁbroma or desmoplastic ﬁbroma was
reported. Intermittently, the pain relieved and the patient
was discharged. Four weeks later, local pain was recurring
and an X-ray control showed progression of the osteolytic
lesion. Hence, curettage and reconstruction with autologous
bone graft of the iliac bone was performed. Again, tissue
specimens,nowdescribedasnon-ossifyingﬁbroma,presented
as a benign process in the histological workup. Decreasing
pain and present stability of the leg allowed the patient’s
discharge. Three months later the patient was reassessed by
open biopsy due to recurrent and increasing pain as well
as swelling of the proximal right tibia. This time, tissue
specimens were analyzed by independent local and reference
pathologists who ﬁnally established the diagnosis of SEF of
the bone. As seen in other cases of SEF the resected tumor
onlystainedpositiveforvimentininimmunohistochemistry.
Routine staging was negative for metastases (CT-scan of the
lung and 18-FDG-PET/CT scan). Clinically, only one single
enlarged lymph node at the right outer thoracic wall was
detected, which, however, showed no tumor cell inﬁltration
on resection biopsy.
Taking into consideration the bone association of the
tumor and the lack of a standardized treatment regimen,
the local interdisciplinary tumor board decided to treat the
patient following the EURAMOS-1 (European-American-
Osteosarcoma-1) protocol designed for the treatment of
osteosarcoma. The EURAMOS-1 treatment plan consists
of chemotherapy elements with Doxorubicin, Cisplatin,
and high-dose Methotrexate [32], and several case reports
describe treatment of patients with SEF with these drugs
[2]. Yet, clinical follow-up and documentation of these cases
is not conclusive enough to predict clinical beneﬁt of this
therapy [2].
After two courses of Cisplatin/Doxorubicin and ﬁve
courses of high-dose Methotrexate our patient under-
went tumor resection and endoprosthetic reconstruction
(Figure 1). The resected tumor specimen revealed marginal
safety distance at the resection boarders. Moreover, the
tumor showed no signs of regression in the resection spec-
imen (grade of regression VI according to Salzer-Kuntschik
[33]) (Figure 2). These ﬁndings prompted the decision
to change the chemotherapy regimen and to introduce a
diﬀerent set of agents. Thus, at this point, in accordance with
the expert panel at the biannual meeting of the GPOH, we
started to treat the patient according to the CWS 2002 High-
Risk protocol (German Cooperative Soft Tissue Sarcoma
Study; Cooperative Weichteilsarkom Studie) designed for
the treatment of soft tissue sarcoma [34]. The adjuvant
chemotherapy was now based on Ifosfamide, Vincristine,
and Actinomycin-D. Altogether the patient received seven
courses of chemotherapy according to CWS 2002 High-Risk
protocol [32, 34] and eight courses of an orally administered
maintenance therapy consisting of Idarubicine, Etoposide,
and Trofosfamide (overview in Figure 3). To date, 22 months
after diagnosis of SEF, the patient is well and attended
regularly in our outpatient clinic. There is no evidence of
relapse and/or metastasis so far.
3. Discussion
In general, SEF appears to be a slowly growing tumor often
present for several months or years before diagnosis. In most
cases of SEF, it took 33 months from the ﬁrst onset of
symptoms to correct diagnosis [2]. The delayed diagnosis (4
months) in our patient once again emphasizes the diﬃcultySarcoma 3
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Figure 1: Pre- and postoperative radiological imaging of the right leg and in situ pictures: (a and b) preoperative conventional X-rays of the
right knee. The tumor shows an eccentric osteolytic lesion located at the epimetaphyseal proximal tibia, not respecting the epiphyseal plate.
The medial cortical bone is completely destroyed and the formation of partially calciﬁed periosteal lining suggests a Lodwick-type 1C lesion.
(c) MRI scan demonstrating a T1 isointense, T2 hypointense tumor formation. A similar zonal architecture with a large central core of
very low signal intensity and a peripheral rim of intermediate to high signal intensity on T1- and T2-weighted spin-echo pulse sequences
was observed by Christensen et al. [30]. (d) MRI scan showing high uptake of Gadolinium predominantly at the tumor’s periphery. A thin
layer of sclerotic bone separates the tumor from circumjacent marrow edema. (e and f) Intraoperative images during tumor resection and
implantation of the endoprosthesis. Resection of the tumor was performed in no-touch technique. The scar of the previous open biopsy
(white arrows) as well as the former access path remained on the resected bone. Reconstruction was accomplished by implanting a partially
custom-madetumorendoprosthesisincombinationwithlinkedkneereplacement.(gandh)Postoperativeradiographsoftherightlegshow
the endoprosthesis in proper position.
Figure 2: H&E staining of sclerosing epithelioid ﬁbrosarcoma after
treatment with neoadjuvant chemotherapy (magniﬁcation ×400).
The tumor is composed of few scattered polynuclear giant cells
(black arrow) and groups of cells, which are rich in cytoplasm and
show pale, vesicular, and irregular nuclei without any substantial
mitotic activity (white arrow). The tumor cells are embedded in a
collagen-richextracellularmatrixanddisplaynosignsofregression.
arising from the inconclusive clinical, radiological, and
histopathological presentation of this tumor. Although the
tumor macroscopically has a circumscript appearance, it
routinely inﬁltrates soft tissues, including periosteum, and
c a ne v e ni n v a d eb o n e[ 1–4, 35]. To our knowledge this is
the third case of a SEF primary arising from the bone [35–
37], which led to the initial clinical diagnosis of ossifying
ﬁbroma in our patient. Indeed, osseous diﬀerentiation of SEF
has been described in the literature and was seen in the ﬁrst
biopsy, but was absent in specimens of the second biopsy [3].
Moreover, inﬁltration of the adjacent bone has previously
been reported [1–4]. Although histomorphology of SEF
suggests being low-grade, it clinically presents as a high-
grade tumor [2, 28]. SEF belongs to the family of ﬁbrosing
ﬁbrosarcomas and appears to be the most malignant variant
of this family of low-grade ﬁbrosarcomas [2]. However, the
highmortalityrateobservedinpatientswithSEFmayalsobe4 Sarcoma
Diagnosis: SEF 100% vitality of tumor cells
AdP M M AdP M M M OP AdP I2VA I2VA I2VAd
14 5 1 0 1 3 1 4 1 6 1 7 2 4 2 83 2 3 6 W e e k
Treatment protocol: EURAMOS-1 CWS 2002 High-Risk
I2VA I2VA I2VA I2VA
Maintenance therapy and follow-up
39 42 46 49 Week
Cumulative doses in 49 weeks (intravenous administration):
Adriamycin (Ad)
Cisplatin (P)
Methotrexate (M)
305mg/m2
360mg/m2
60000mg/m2
Ifosfamide (I)
Vincristine (V)
Actinomycin-D (A)
42000mg/m2
13.5mg/m 2
9mg/m 2
Cumulative doses of maintenance therapy in 26 weeks (oral administration):
Etoposide
Trofosfamide
Idarubicine
2000mg/m2
12000mg/m2
80mg/m2
Figure 3: Schematic illustration of the treatment regimen including cumulative dosages of the chemotherapeutic drugs. Each chemotherapy
cycle of the main therapy is depicted as a yellow box, and the week when the cycle started is shown below. The time point of surgery and
implantation of endoprosthesis is indicated with a red box (OP). The regimens of the maintenance therapy and follow-up are not displayed
in detail.
duetothelackofexperienceofmostofthephysiciansinhow
to treat patients with SEF potentially leading to inadequate
therapy and unfavorable outcome [2].
4. Conclusion
Due to the rareness of this tumor, there are no established
treatment regimens. So far, patients have been treated with
amputation,wide excision, radio- andchemotherapy,or var-
ious combinations thereof [2]. Our experience showed that
Doxorubicin, Methotrexate, and Cisplatin had no signiﬁcant
eﬀect on tumor vitality. This information and the fact that
SEF clinically presents with features of high-grade tumors
should be considered when deciding on the treatment. The
role of systemic therapy, however, still remains unclear.
Future follow-up of our patient will demonstrate whether
chemotherapy according to the CWS-protocol and tumor
resection can prevent the development of metastasis and
relapse.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
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